Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has shared an announcement.
Shanghai Junshi Biosciences Co., Ltd. announced the successful passing of all resolutions during its 2025 first extraordinary general meeting. The meeting saw significant participation from shareholders, with a notable percentage of shares represented. Key resolutions included the election of an Independent Non-executive Director and amendments to internal management policies, reflecting the company’s strategic focus on governance and operational efficiency.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biotechnology company based in China, focusing on the development, production, and commercialization of innovative drugs, particularly in the field of immuno-oncology.
Average Trading Volume: 13,139,562
Technical Sentiment Signal: Buy
Current Market Cap: HK$42B
Find detailed analytics on 1877 stock on TipRanks’ Stock Analysis page.